Pictet Asset Management (Switzerland)’s Vertex Pharmaceuticals VRTX Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$379M	Sell	1,075,836 -100,477	-9%	-$33.9M	0.45%	53
2023 Q1	$371M	Buy	1,176,313 +201,301	+21%	+$60.4M	0.46%	48
2022 Q4	$282M	Buy	975,012 +192,229	+25%	+$58.6M	0.41%	59
2022 Q3	$227M	Buy	782,783 +59,632	+8%	+$17.2M	0.34%	83
2022 Q2	$204M	Sell	723,151 -184,515	-20%	-$49.4M	0.28%	104
2022 Q1	$237M	Sell	907,666 -304,653	-25%	-$72.3M	0.27%	114
2021 Q4	$266M	Buy	1,212,319 +147,497	+14%	+$28.7M	0.27%	107
2021 Q3	$193M	Buy	+1,064,822	New	+$208M	0.21%	136

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s VRTX Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) reduced its Vertex Pharmaceuticals (VRTX) stake by 8.5% in Q2 2023, selling an estimated $33.9M and leaving 1,075,836 shares worth $379M. The position accounts for 0.45% of the portfolio, ranked #53.

Pictet Asset Management (Switzerland) first reported a position in VRTX in Q3 2021 and has held it in 8 quarters since. 1,286 funds tracked by Wall St. Rank hold VRTX as of Q2 2023.

Pictet Asset Management (Switzerland) held 1,075,836 shares of Vertex Pharmaceuticals worth $379M as of Q2 2023.
Pictet Asset Management (Switzerland) sold 100,477 Vertex Pharmaceuticals shares in Q2 2023, an estimated $33.9M.
Vertex Pharmaceuticals made up 0.45% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #53 holding.
Pictet Asset Management (Switzerland) first reported a position in Vertex Pharmaceuticals in Q3 2021 and has held it in 8 quarters since.
1,286 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.